System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42368197 DOI: 10.1002/nep3.70033

Increased expression of aromatase after focal cerebral ischemia: Relevance to neuroprotection and functional recovery.

Neuroprotection 4(2):143-156

Authors: Lindsay Gallagher, Anna F Dominiczak, Luis M Garcia-Segura, Nobuhiro Harada, J B Hutchison, James M Mullin, Delyth Graham, Peter O'Shaughnessy, Hilary Victoria O Carswell

Affiliations

  • Institute of Neuroscience and Psychology, College of Medicine, Veterinary and Life Science University of Glasgow Glasgow Scotland UK.
  • BHF Glasgow Cardiovascular Research Center University of Glasgow Glasgow Scotland UK.
  • Cajal Institute Madrid Spain.
  • Fujita Health University Toyoake Aichi Japan.
  • Babraham Institute Cambridge England UK.
  • School of Biodiversity, One Health & Veterinary Medicine, University of Glasgow Glasgow Scotland UK.
  • Strathclyde Institute of Pharmacy and Biological Sciences University of Strathclyde Glasgow Scotland UK.

Abstract

AIM

Aromatase is the key enzyme in the biosynthesis of 17β-estradiol, the most potent estrogen, which has pleiotropic neuroprotective properties. Aromatase levels increase in the brain after stroke, and its gene variants increase susceptibility to stroke. This study aims to determine whether aromatase overexpression improves stroke outcome and whether aromatase inhibition exacerbates outcome after permanent focal cerebral ischemia.

METHODS/DESIGN

All animals (3-4 months old) underwent permanent middle cerebral artery occlusion (MCAO) by diathermy. Time course of aromatase expression following MCAO in female ovariectomized spontaneously hypertensive stroke prone (SHRSP) rats was assessed by semi-quantitative immunohistochemistry and quantitative polymerase chain reaction (qPCR). The effect of aromatase expression on stroke outcome was assessed using a male mouse model over-expressing aromatase (Dax-1 KO mice) and by letrozole treatment. Volume of ischemic damage was assessed by magnetic resonance imaging (MRI) and functional recovery was assessed by the corner test and foot-fault test. All analyses were performed using GraphPad Prism version 9.0.

RESULTS

The key findings are that aromatase expression was significantly increased in SHRSP in both the dorsal and ventral peri-infarct zones and hippocampus at 24 h post-MCAO as measured by areas of immunostaining but not qPCR. There was no improvement in stroke outcome by Dax-1 KO, despite significantly higher plasma 17β-estradiol levels and increased brain aromatase immunoreactivity after stroke. There was no exacerbation on stroke outcome by letrozole, despite decreased plasma 17β-estradiol levels.

CONCLUSION

The time course and location of increased aromatase indicate a potential role in neuroprotection and repair; however, manipulation of aromatase expression does not influence outcome after permanent MCAO in male mice.

MeSH

Estrogens, Aromatase, Stroke, Estradiol, Brain, Letrozole, Neuroprotection, Recycling, Ischemia, Plasma